(4S,4'S)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4-异丙基恶唑],98%,(99%ee) (4S,4'S)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4-isopropyloxazole], 98%, (99% ee)
-
(4R,4'R)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4-异丙基恶唑],98%,(99%ee) (4R,4'R)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4-isopropyloxazole], 98%, (99% ee)
ZMR-07-1434 | 100mg
-
(4R,4'R)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4-叔丁基恶唑],98%,(99%ee ) (4R,4'R)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4-tert-butyloxazole], 98%, (99% ee)
ZMR-07-1082 | 100mg
-
(4S,4'S)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4-异丙基噁唑 (4S,4'S)-2,2'-(2,3-Dihydro-1H-indene-2,2-diyl)bis(4-isopropyl-4,5-dihydrooxazole)
V82714-100mg | 100mg
-
(4R,4'R,5S,5'S)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4,5-二苯基恶唑],98% (4R,4'R,5S,5'S)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4,5-diphenyloxazole], 98%
ZMR-07-1085 | 100mg
-
(4S,4'S)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4-(苯甲基)噁唑] (4S,4'S)-2,2'-(2,3-Dihydro-1H-indene-2,2-diyl)bis(4-benzyl-4,5-dihydrooxazole)
R097997-100mg | 100mg
-
(4S,4'S)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4-phenyloxazole]
V15178-100mg | 100mg
-
(4S,4'S)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4-叔丁基噁唑 (4S,4'S)-2,2'-(2,3-Dihydro-1H-indene-2,2-diyl)bis(4-(tert-butyl)-4,5-dihydrooxazole)
V82717-250mg | 250mg
中文名称:(4S,4'S)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4-异丙基恶唑],98%,(99%ee)
英文名称:(4S,4'S)-2,2'-(1,3-Dihydro-2H-inden-2-ylidene)bis[4,5-dihydro-4-isopropyloxazole], 98%, (99% ee)
分子式:C21H28N2O2;分子量:340.5;储存条件:Store at 2-8℃。
您正在浏览的产品:(4S,4'S)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4-异丙基恶唑],98%,(99%ee)
手机版:(4S,4'S)-2,2'-(1,3-二氢-2H-茚满-2-亚烷基)双[4,5-二氢-4-异丙基恶唑],98%,(99%ee)
本公司销售的所有产品仅供实验科研使用,不用于人体及临床诊断。
2. 色谱条件优化:调整流动相比例使主峰与杂质峰分离度≥2.0
3. 进样分析:进样量10 μL,记录色谱图并计算ee值
2. 流动相应现配现用并超声脱气
3. 含异丙基等疏水基团的化合物需延长平衡时间至30分钟
以上信息仅供参考,请以相应标准的原文为准!